Elevated levels of wild-type p53 in testicular tumors may contribute to their sensitivity to DNA damaging drugs and explain their high cure rate (pages 804–810).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49–53 (1991).
Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–52 (1993).
Bartkova, J. et al. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int. J. Cancer 49, 196–202 (1991).
Riou, G. et al. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog. 12, 124–131 (1995).
Peckham, M.J., Horwich, A. & Hendry, W.F. Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br. J. Cancer 52, 7–13 (1985).
Lutzker, S. & Levine, A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med. 2, 804–810 (1996).
Hupp, T.R., Sparks, A. & Lane, D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237–45 (1995).
Canman, C.E., Gilmer, T.M., Coutts, S.B. & Kastan, M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9, 600–611 (1995).
Barak, Y., Gottlieb, E., Juven, G.T. & Oren, M. Regulation of mdm2 expression by p53i Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739–49 (1994).
Chresta, C.M., Masters, J.R.W. & Hickman, J.A. Hypersensitivity of human testicular tumours to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56, 1834–1841 (1996).
Montes, d.O.L.R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203–206 (1995).
Hecker, D., Page, G., Lohrum, M., Weiland, S. & Scheidtmann, K.H. Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 12, 953–961 (1996).
Hall, S.R., Campbell, L.E. & Meek, D.W. Phosphorylation of p53 at the casein kinase site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24, 1119–1126 (1996).
Hawkins, D.S., Demers, G.W. & Galloway, D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892–898 (1996).
Cordon, C.C. et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794–799 (1994).
Fry, A.M. et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51, 6592–6595 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chresta, C., Hickman, J. Oddball p53 in testicular tumors. Nat Med 2, 745–746 (1996). https://doi.org/10.1038/nm0796-745
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0796-745
This article is cited by
-
Molecular Aspects of Ultraviolet Radiation-induced Apoptosis in the Skin
Journal of Cutaneous Medicine and Surgery (2005)
